These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 14532138)

  • 21. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Hochman D; Wolff B
    JAMA; 2006 Nov; 296(18):2203; author reply 2203-4. PubMed ID: 17090763
    [No Abstract]   [Full Text] [Related]  

  • 22. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Callegari PE; Schaible TF; Boscia JA
    JAMA; 2006 Nov; 296(18):2202; author reply 2203-4. PubMed ID: 17090762
    [No Abstract]   [Full Text] [Related]  

  • 23. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Costenbader KH; Glass R; Cui J; Shadick N
    JAMA; 2006 Nov; 296(18):2201; author reply 2203-4. PubMed ID: 17090761
    [No Abstract]   [Full Text] [Related]  

  • 24. The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.
    Hernández MV; Sanmartí R; Cañete JD
    Expert Opin Drug Saf; 2016 May; 15(5):613-24. PubMed ID: 26927029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The NICE reappraisal of biologics in 2005: what rheumatologists need to know.
    Bansback NJ; Young A; Brennan A
    Rheumatology (Oxford); 2005 Jan; 44(1):3-4. PubMed ID: 15328422
    [No Abstract]   [Full Text] [Related]  

  • 26. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Okada SK; Siegel JN
    JAMA; 2006 Nov; 296(18):2201-2; author reply 2203-4. PubMed ID: 17090760
    [No Abstract]   [Full Text] [Related]  

  • 27. [Modern therapy of rheumatoid arthritis. Joint destruction can be delayed].
    Neumaier J
    MMW Fortschr Med; 2008 Apr; 150(14):14. PubMed ID: 18488571
    [No Abstract]   [Full Text] [Related]  

  • 28. Role of biological agents in immune-mediated inflammatory diseases.
    Efthimiou P; Markenson JA
    South Med J; 2005 Feb; 98(2):192-204. PubMed ID: 15759950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Redefining treatment of rheumatic arthritis with anti-cytokines].
    Gabay C; So A
    Rev Med Suisse; 2007 Mar; 3(103):715-7. PubMed ID: 17458148
    [No Abstract]   [Full Text] [Related]  

  • 30. Unstable diabetes in a patient receiving anti-TNF-alpha for rheumatoid arthritis.
    Boulton JG; Bourne JT
    Rheumatology (Oxford); 2007 Jan; 46(1):178-9. PubMed ID: 16998233
    [No Abstract]   [Full Text] [Related]  

  • 31. Risk of lymphoma in patients with RA treated with anti-TNFalpha agents.
    Franklin JP; Symmons DP; Silman AJ
    Ann Rheum Dis; 2005 May; 64(5):657-8. PubMed ID: 15834052
    [No Abstract]   [Full Text] [Related]  

  • 32. Assessing the value of rheumatoid arthritis treatment alternatives: the potential effect of tumor necrosis factor inhibitors.
    Mizutani W
    Manag Care Interface; 2003 Mar; 16(3):44-50, 55. PubMed ID: 12715413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F
    Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [When are "biologics" indicated?].
    MMW Fortschr Med; 2006 Apr; 148(17):10. PubMed ID: 16711479
    [No Abstract]   [Full Text] [Related]  

  • 35. Advances in targeted therapies V: Proceedings of the 5th International Symposium. St Martin, French West Indies. 11-14 April 2003.
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2():ii1-96. PubMed ID: 14532137
    [No Abstract]   [Full Text] [Related]  

  • 36. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
    Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
    Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in use of immunomodulatory agents--a rheumatology perspective.
    Her M; Kavanaugh A
    Nat Rev Gastroenterol Hepatol; 2015 Jun; 12(6):363-8. PubMed ID: 25895821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serious infections with antirheumatic therapy: are biologicals worse?
    Winthrop KL
    Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii54-7. PubMed ID: 17038474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence that cytokines play a role in rheumatoid arthritis.
    Brennan FM; McInnes IB
    J Clin Invest; 2008 Nov; 118(11):3537-45. PubMed ID: 18982160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis.
    Flendrie M; Creemers MC; Welsing PM; den Broeder AA; van Riel PL
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii30-3. PubMed ID: 14532145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.